Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Neuro-focused Inexia/Orexia spun off by Sosei Heptares with €40mm in Medicxi funding

Executive Summary

Sosei Heptares (formerly Sosei Group Corp.) spun off two independent companies, Inexia Ltd. and Orexia Ltd., which will focus on developing neurological disease therapies based on Sosei subsidiary Heptares Therapeutics Ltd.'s orexin-positive G protein-coupled receptor (GPCR) modulators OX1 and OX2. Medicxi is investing in both companies with an aggregate amount of up to €40mm ($45.8mm).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Spin-Off

Related Companies

Advertisement
UsernamePublicRestriction

Register